| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $350K | — |
| Cost of Revenue | $539K | — |
| R&D Expense | $44.7M | +38.3% |
| SG&A Expense | $32.0M | +33.9% |
| Operating Income | -$76.9M | -36.8% |
| Pre-tax Income | $72.8M | +235.9% |
| Income Tax | $0 | — |
| Net Income | -$72.8M | -35.8% |
| EPS (Basic) | -$1.08 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $80.7M | -31.6% |
| Accounts Receivable | $274K | — |
| Inventory | $136K | — |
| Current Assets | $83.4M | -30.2% |
| Total Assets | $94.5M | -28.6% |
| Current Liabilities | $7.9M | -21.2% |
| Total Liabilities | $13.9M | -21.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$54.1M | -48.9% |
| Capital Expenditures | $315K | +152.0% |
| Investing Cash Flow | -$335K | -168.0% |
| Financing Cash Flow | $17.2M | -84.4% |
| Free Cash Flow | -$54.4M | -49.3% |
| Stockholders' Equity |
| $80.7M |
| -29.8% |